Cell line · CVCL_1600
NCI-H929
Cancer cell line, Homo sapiens. Plasma cell myeloma. 68 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H929. Cell lines, record CVCL_1600. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1600
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H929
- Accession
- CVCL_1600
- RRID
- RRID:CVCL_1600
- Synonyms
- NCI H929, NCIH929, H929, H-929
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 62Y
- Category
- Cancer cell line
- Diseases
- Plasma cell myeloma (NCIt C3242); Multiple myeloma (ORDO Orphanet_29073)
- Derived from
- Pleural effusion (in situ)
- Cell type
- Plasma cell
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers68
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib. | Br J Haematol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. | Blood Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 68
See all 68 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE NCI-H929-CopGFP | CVCL_F6AD | Cell lines | |
| Derived from it | EDITGENE NCI-H929-FLUC | CVCL_F5T4 | Cell lines | |
| Derived from it | NCI-H929B | CVCL_M400 | Cell lines |
Cell banks9
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-3580 | ATCC | |
| ATCC | CRL-9068 | Discontinued | Cellosaurus |
| BCRC | 60386 | BCRC | |
| CCTCC | GDC0300 | Cellosaurus | |
| CLS | 305236 | CLS | |
| DSMZ | ACC-163 | DSMZ | |
| ECACC | 95050415 | ECACC | |
| EDITGENE | EDC00232 | EDITGENE | |
| Hysigen | TCH-C429 | Hysigen |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1600
GET https://conductscience.org/api/cell-lines/v1/CVCL_1600/papers?page=2